This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Tolerability Study of ARC-520 in Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
Arrowhead Pharmaceuticals Identifier:
First received: June 4, 2013
Last updated: December 9, 2014
Last verified: December 2014
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of ARC-520 in normal, adult volunteers.

Condition Intervention Phase
Healthy Drug: ARC-520 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers

Further study details as provided by Arrowhead Pharmaceuticals:

Primary Outcome Measures:
  • To determine the incidence and frequency of adverse events as a measure of safety and tolerability of ARC-520 [ Time Frame: One month ]
    The incidence and frequency of adverse events (AEs), serious adverse events (SAEs), related AEs, related SAEs, and AEs leading to withdrawal, dose modification, or treatment discontinuation will be summarized by dose and treatment group.

Secondary Outcome Measures:
  • To evaluate the pharmacokinetics of ARC-520 at different dose concentrations [ Time Frame: 2 days ]
    Plasma concentrations following a single dose of ARC-520 at different dose levels will be used to calculate the following ARC-520 pharmacokinetic parameters: Cmax, tmax, AUC0-24, AUCinf, and t1/2. Descriptive statistics of pharmacokinetic parameters will include mean, standard deviation, and coefficient of variation.

Enrollment: 54
Study Start Date: July 2013
Study Completion Date: November 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ARC-520
Single dose, intravenous administration of ARC-520.
Drug: ARC-520
Placebo Comparator: Normal Saline
Single dose, intravenous administration of Normal Saline
Drug: Placebo


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Key Inclusion Criteria:

  • Healthy male or female subjects, 18-55 years of age
  • Be a non-smoker

Key Exclusion Criteria:

  • History of clinically relevant medical illnesses that in the Investigator opinion may jeopardize subject safety or interfere with participation in the study, including but not limited to hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
  • Acute signs of hepatitis/other infection (e.g., moderate fever, jaundice, nausea, vomiting, abdominal pain) evident within 4 weeks of screening and/or at the screening examination.
  • Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of study treatment.
  • Is sero-positive for HIV, HBV, HCV, and/or a history of delta virus hepatitis.
  • Currently uses and/or has a history of alcohol and/or drug abuse < 12 months from screening.
  • Use of investigational agents or devices within 30 days prior to planned study dosing or current participation in an investigational study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01872065

Australia, Victoria
Nucleus Network Ltd.
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Arrowhead Pharmaceuticals
Principal Investigator: Jason Lickliter, MD, PhD Nucleus Network Ltd
  More Information

Responsible Party: Arrowhead Pharmaceuticals Identifier: NCT01872065     History of Changes
Other Study ID Numbers: Heparc-1001
Study First Received: June 4, 2013
Last Updated: December 9, 2014 processed this record on July 21, 2017